The First WHO integrated meeting on development and clinical trials of Influenza vaccines that induce broadly protective and long-lasting immune responses
24–26 January 2013, Hong Kong Baptist University, Hong Kong SAR, China
Meeting summary and day one selected presentations
Selected presentations - Day one, 24 January 2013
-
SAGE recommendations for seasonal influenza vaccines: further evidence needs.
pdf, 1.28Mb
John Tam, WHO, Switzerland -
Clinical evaluation of universal influenza vaccines and pipelines for new influenza vaccines
pdf, 1.04Mb
Robert Huebner, United States Department of Health and Human Services, ASPR, USA -
Antigenic targets for broadly protective and universal influenza vaccines
pdf, 480kb
Florian Krammer, Mount Sinai School of Medicine, USA -
Broadly protective and universal influenza vaccines Immune responses and correlates of protection
pdf, 2.22Mb
Guus Rimmelzwaan, Erasmus Medical Center, Netherlands -
COBRA: A novel strategy for developing a broadly reactive vaccine against emerging H5N1 influenza
pdf, 2.74Mb
Ted Ross, University of Pittsburgh, Center for Vaccine Research, USA -
Re-engineering HA-1 protein sequences as a means to developing universal influenza vaccines
pdf, 984kb
Harold Kleanthous, Sanofi Pasteur, USA -
Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity
pdf, 6.99Mb
Alain Townsend, Oxford University, UK -
Development of “universal” immunogens against HPAI H5N1 viruses and beyond
pdf, 901kb
Paul Zhou, Shanghai Institute for Biological Sciences, China -
Improving influenza vaccine virus selection and development process
pdf, 2.99Mb
Wenqing Zhang, WHO, Switzerland -
Review on evidence for influenza vaccine strains selection
pdf, 3.11Mb
Jackie Katz, CDC, USA -
H5N1 and H7 LAIV-IAV prime-boost studies
pdf, 161kb
Kanta Subbarao, NIAID-NIH, USA -
Clinical trials of live attenuated H7N3 vaccine
pdf, 2.01Mb
Larisa Rudenko, Institute of Experimental Medicine, Russia -
Clinical trials of H5N2 LAIV in Thailand
pdf, 390kb
Punnee Pitisuttithum, Mahidol University, Thailand -
Quadrivalent influenza vaccine developments
pdf, 2.44Mb
Timo Vesikari, University of Tampere, Finland -
High dose inactivated influenza vaccines
pdf, 941kb
Baylor College of Medicine, USA -
Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine
pdf, 1.97Mb
Irina Isakova-Sivak, Institute of Experimental Medicine, Russia -
A novel replication-deficient Influenza vaccine based on deletion of M2
pdf, 1.60Mb
Pamuk Bilsel, FluGen Inc., USA -
The production and delivery of edible plant- and lactobacteria-derived vaccines
pdf, 1.93Mb
Dominic Man-Kit Lam, Hong Kong Baptist University, Hong Kong